Compare Fox Corp Class A (FOXA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Summit Therapeutics Inc — how do they compare? Fox Corp Class A trades at $62.43 (market cap $24.58B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Fox Corp Class A is far larger — about 2× Summit Therapeutics Inc's market cap, and Fox Corp Class A pays a 0.93% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FOXA | SMMT | |
|---|---|---|
Market Cap | $24.58B | $12.06B |
Sector | Media | Health |
52-Week High | $76.11 | $26.98 |
52-Week Low | $48.79 | $12.55 |
Enterprise Value | $27.94B | $11.39B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $63.05, down 0.58% today, with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.79 surpassing the $1.44 estimate, and revenue growth from $14.0B in 2024 to $16.3B in 2025. Recent news highlights World Cup-driven ad revenue and Tubi streaming growth as key catalysts.
The outlook is positive with a $65.33 consensus price target and 50% analyst buy ratings, but risks include declining 2026 net income projections and high RSI levels suggesting overbought conditions. The stock offers value with a P/E of 16.18 and robust cash flow, though investors should monitor sports cost pressures and debt levels.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
